이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Esperion Therapeutics 관리

관리 기준 확인 3/4

Esperion Therapeutics' CEO는 Sheldon Koenig, May2021 에 임명되었습니다 의 임기는 3.08 년입니다. 총 연간 보상은 $ 2.97M, 24.3% 로 구성됩니다. 24.3% 급여 및 75.7% 보너스(회사 주식 및 옵션 포함). 는 $ 446.59K 가치에 해당하는 회사 주식의 0.087% 직접 소유합니다. 446.59K. 경영진과 이사회의 평균 재임 기간은 각각 2.3 년과 2.9 년입니다.

주요 정보

Sheldon Koenig

최고 경영자

US$3.0m

총 보상

CEO 급여 비율	24.3%
CEO 임기	3.3yrs
CEO 소유권	0.09%
경영진 평균 재임 기간	2.5yrs
이사회 평균 재임 기간	3.1yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Sheldon Koenig 의 보수는 Esperion Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$98m
Mar 31 2024	n/a	n/a	-US$87m
Dec 31 2023	US$3m	US$721k	-US$209m
Sep 30 2023	n/a	n/a	-US$208m
Jun 30 2023	n/a	n/a	-US$222m
Mar 31 2023	n/a	n/a	-US$239m
Dec 31 2022	US$4m	US$683k	-US$234m
Sep 30 2022	n/a	n/a	-US$243m
Jun 30 2022	n/a	n/a	-US$258m
Mar 31 2022	n/a	n/a	-US$235m
Dec 31 2021	US$8m	US$566k	-US$269m
Sep 30 2021	n/a	n/a	-US$308m
Jun 30 2021	n/a	n/a	-US$325m
Mar 31 2021	n/a	n/a	-US$156m
Dec 31 2020	US$508k	US$23k	-US$144m

보상 대 시장: Sheldon 의 총 보상 ($USD 2.97M )은 UK 시장( $USD 978.01K ).

보상과 수익: Sheldon 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Sheldon Koenig (58 yo)

3.3yrs

테뉴어

US$2,968,565

보상

Mr. Sheldon L. Koenig has been President, Chief Executive Officer and Director at Esperion Therapeutics, Inc. since May 17, 2021 and had been its Chief Operating Officer since December 15, 2020 until May 1...

리더십 팀

이름	위치	테뉴어	보상	소유권
Sheldon Koenig	President	3.3yrs	US$2.97m	0.087% $ 287.7k
Eric Warren	Chief Commercial Officer	2.5yrs	US$1.08m	0.083% $ 273.3k
Benjamin Halladay	Chief Financial Officer	1.8yrs	데이터 없음	0.12% $ 409.8k
Glenn Brame	Chief Technical Operations Officer	1.7yrs	데이터 없음	데이터 없음
Benjamin Looker	General Counsel & Corporate Secretary	2.7yrs	US$1.29m	0.094% $ 308.6k
Tiffany Aldrich	Associate Director of Corporate Communications	no data	데이터 없음	데이터 없음
Betty Swartz	Chief Business Officer	no data	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: 0IIM 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Sheldon Koenig	President	3.3yrs	US$2.97m	0.087% $ 287.7k
Nicole Vitullo	Lead Independent Director	16.4yrs	US$94.78k	0.016% $ 53.4k
Alan Fuhrman	Independent Non-Employee Director	4.5yrs	US$104.78k	0.027% $ 89.7k
Antonio Gotto	Independent Director	10.7yrs	US$82.28k	0.026% $ 86.7k
Jay Shepard	Independent Director	6.3yrs	US$97.28k	0.026% $ 86.7k
Stephen Rocamboli	Independent Director	2.4yrs	US$94.78k	0.018% $ 60.9k
J. Carroll	Independent Chairperson	2.3yrs	US$117.28k	0.033% $ 108.6k
Peter Libby	Member of Scientific Advisory Board	2.1yrs	데이터 없음	데이터 없음
Seth H. Fischer	Independent Director	2.9yrs	US$99.78k	0.014% $ 47.3k
Tracy Woody	Independent Director	5.3yrs	US$91.97k	0.014% $ 47.7k
Erin Bohula	Member of Scientific Advisory Board	2.1yrs	데이터 없음	데이터 없음
Jeffrey Bender	Member of Scientific Advisory Board	2.1yrs	데이터 없음	데이터 없음

3.1yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: 0IIM 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

Esperion Therapeutics 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Esperion Therapeutics, Inc., Annual General Meeting, May 23, 2024

Esperion Therapeutics, Inc. Appoints Ben Halladay as Chief Financial Officer

High number of new directors

High number of new directors

High number of new directors

Esperion Appoints J. Martin Carroll to Its Board of Directors

Recent updates

Esperion Therapeutics, Inc. Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe)

Second quarter 2024 earnings released: US$0.33 loss per share (vs US$0.46 loss in 2Q 2023)

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Esperion Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Forecast breakeven date moved forward to 2024

First quarter 2024 earnings released: EPS: US$0.36 (vs US$0.79 loss in 1Q 2023)

Esperion Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Esperion Therapeutics, Inc., Annual General Meeting, May 23, 2024

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Full year 2023 earnings released: US$2.03 loss per share (vs US$3.52 loss in FY 2022)

Esperion Therapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Esperion Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $85.05 million.

U.S. FDA Updates LDL-C Lowering Indication for Esperion's NEXLETOL®? (bempedoic Acid) Tablet and NEXLIZET®? (bempedOic Acid and ezetimibe) Tablet

New major risk - Shareholder dilution

Partners Announce Transform Trial to Evaluate Personalized Heart Disease Care Strategies At American Heart Association 2023

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.81 loss in 3Q 2022)

No longer forecast to breakeven

Esperion Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Market cap size

Forecast to breakeven in 2024

New major risk - Shareholder dilution

Forecast to breakeven in 2024

Second quarter 2023 earnings released: US$0.46 loss per share (vs US$1.05 loss in 2Q 2022)

Forecast to breakeven in 2024

Esperion Therapeutics, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet

Esperion Therapeutics, Inc. Announces the Results from its Pre-Specified, Primary Prevention Clear Outcomes Subgroup Analysis

Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment At Endo 2023

Forecast breakeven date moved forward to 2024

Esperion Announces Submission of Supplemental New Drug Applications to U.S. Fda for Nexletol(R) (Bempedoic Acid) Tablet and Nexlizet(R) (Bempedoic Acid and Ezetimibe) Tablet

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

First quarter 2023 earnings released: US$0.79 loss per share (vs US$0.93 loss in 1Q 2022)

Full year 2022 earnings released: US$3.52 loss per share (vs US$9.31 loss in FY 2021)

Esperion Therapeutics, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Esperion Therapeutics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2022

Esperion Therapeutics, Inc. Announces CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology

Esperion Therapeutics, Inc. Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint

Esperion Therapeutics, Inc. Appoints Ben Halladay as Chief Financial Officer

High number of new directors

Third quarter 2022 earnings released: US$0.81 loss per share (vs US$2.62 loss in 3Q 2021)

Esperion Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Esperion Announces Bempedoic Acid NEXLETOL Recommends as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway

Second quarter 2022 earnings released: US$1.05 loss per share (vs US$1.67 loss in 2Q 2021)

High number of new directors

Esperion Therapeutics, Inc. to Report Q2, 2022 Results on Aug 02, 2022

High number of new directors

Esperion Appoints J. Martin Carroll to Its Board of Directors

High number of new directors

First quarter 2022 earnings released: US$0.93 loss per share (vs US$3.50 loss in 1Q 2021)

High number of new directors

Esperion Therapeutics, Inc. to Report Q1, 2022 Results on May 03, 2022

Esperion Therapeutics, Inc., Annual General Meeting, May 26, 2022

Esperion Therapeutics, Inc. Announces Appointment of Eric Warren, R.Ph. as Chief Commercial Officer

Forecast to breakeven in 2024

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Esperion Therapeutics, Inc. to Report Q4, 2021 Results on Feb 22, 2022

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2024

Esperion Therapeutics, Inc. Provides Earnings Results for the Fourth Quarter of 2021

Third quarter 2021 earnings released: US$2.62 loss per share (vs US$3.07 loss in 3Q 2020)

Forecast to breakeven in 2023

Second quarter 2021 earnings released: US$1.67 loss per share (vs US$4.50 profit in 2Q 2020)

Robbins Geller Rudman & Dowd LLP and Kahn Swick & Foti, LLC Announces Proposed Settlement in the Esperion Therapeutics Securities Settlement

First quarter 2021 earnings released: US$3.50 loss per share (vs US$2.84 loss in 1Q 2020)

Esperion Announces Publication of Rationale and Design of Landmark Clear Cardiovascular Outcomes Trial Evaluating Nexletol (Bempedoic Acid) Tablet in American Heart Journal

Esperion Therapeutics, Inc. Announces the Results of Phase 2 Study Evaluating the Combination of Nexletol® (Bempedoic Acid) 180 Mg Tablet, Ezetimibe 10 Mg and Atorvastatin 20 Mg in Patients with Hypercholesterolemia